Traditional Chinese medicinal composition for treating Yin deficiency and internal heat type lung cancerous hydrothorax

Abstract

The invention belongs to the technical field of medicine, in particular relates to a traditional Chinese medicinal composition for treating Yin deficiency and internal heat type lung cancerous hydrothorax. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicines in parts by weight: 4 to 8 parts of root of dunn antictrema, 4 to 8 parts of dendrobium moniliforme, 4 to 8 parts of leaf of pilose combretum, 4 to 8 parts of radix knoxiae, 4 to 8 parts of ginkgo root, 4 to 8 parts of whole herb of aechmanthera tomentosa, 4 to 8 parts of flower of rice bean, 4 to 8 parts of fuzhou diospyros root and 4 to 8 parts of radix glycyrrhizae. The medicine is combined to jointly realize the efficacy of nourishing Yin and clearing away heat, and removing retained water and morbid fluid; according to the traditional Chinese medicinal composition, lung cancerous hydrothorax can be significantly reduced, and the survival quality of patients is improved.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine composition for treating lung cancer pleural effusion of yin deficiency and internal heat type. Background technique [0002] Lung cancer pleural effusion is one of the most common complications of advanced lung cancer. The average survival period is 3.1 ± 0.5 months, the mortality rate within 1 month is 5.4%, and the mortality rate within 6 months is 84%. Quality of life and survival time of patients. The current treatments mainly include systemic chemotherapy and local pleural perfusion chemotherapy, which have high toxicity and side effects, and are difficult for many advanced patients to accept. Therefore, controlling pleural effusion, relieving symptoms, and improving the quality of life are the main purposes of treating pleural effusion in advanced lung cancer. Therefore, the research on lung cancer pleural effusion has become a...

AI Technical Summary

Problems solved by technology

[0003] Lung cancer pleural effusions are mostly late-stage cancers, and the opportunity for surgical treatment is lost. Clinically, medical palliative care is mainly used to relieve symptoms and relieve pain. However, systemic chemotherapy and local pleural perfusion chemotherapy for the primary tumor are difficult to control pleural effusion, and the side effects are large. Simple pleural puncture can temporarily relieve symptoms, but the fluid can quickly reassemble, and repeated aspiration will consume protein and immune cells, making the patient's body weaker and weaker, and hypoproteinemia can aggravate the reassembly of pleural effusion At the same time, it can also lead to effusion parcels, and even half of the patients are complicated by infection to make the disease progress. Therefore, only by pumping pleural effusion, systemic and local chemotherapy can not solve the reunion of pleural effusion, and the curative effect is very unsatisfactory. Physical strength is exhausting, which significantly reduces the physical fitness of cancer patients, affecting the survival period and quality of life of patients

[0004] Yin-deficiency and internal-heat type is a common type of lung cancer pleural effusion, and there is no specific drug for this type of lung cancer pleural effusion